Zealand Pharma

Board/Management Information • Dec 15, 2014

Copenhagen, 2014-12-15 09:45 CET (GLOBE NEWSWIRE) -- Company Announcement

No. 20/2014

Copenhagen, 15 December 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq
Copenhagen: ZEAL) announced today that Senior Vice President and Chief Business
Officer, Dr. Arvind Hundal, has stepped down to pursue other opportunities
outside the company.

Arvind Hundal joined Zealand in 2009 and was nominated to the position of Chief
Business Officer in 2011, at which time she also joined the company’s Executive
Management team.

In a comment to this announcement, David Solomon, President and CEO of Zealand,
said:

“Arvind Hundal has made valuable contributions to building Zealand’s large
portfolio of partnership agreements over the past five years. It is to a large
extent also thanks to Arvind and the team’s achievements that Zealand today
stands with a solid platform from which to move to the next level in its
development, and we wish her all the best in her next endeavors.”

                                  ***

For further information, please contact:

David Solomon, President and Chief Executive Officer

Tel: +45 22 20 63 00

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences also in clinical trial design and management with a
therapeutic focus on metabolic diseases and acute care indications. The company
is advancing a proprietary pipeline of novel medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory filing of Lyxumia® is planned for summer 2015 and of LixiLan as
early as end 2015.

Zealand proprietary pipeline includes danegaptide (prevention of ischemic
reperfusion injury) and the stable glucagon analogue, ZP4207 (treatment of
severe hypoglycemia) as well as several preclinical peptide therapeutics.
Partnering represents an important component of strategy to leverage in-house
expertise, share development risk in large clinical trials, provide funding and
commercialize the company’s products. Zealand currently has global license
agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer
Ingelheim and Eli Lilly.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma